CLSD Clearside: Enterprise Value to EBITDA Ratio

Clearside Biomedical, Inc. - graphic logo of issuer CLSD

Clearside Biomedical (CLSD) business relies on stable demand in ophthalmology, which remains independent of economic downturns. The company possesses exclusive technology for targeted drug delivery via microneedles, creating a robust barrier for major players. However, R&D costs and payment timelines from counterparties create certain pressure. This price chart featuring the 0.00 metric visualizes the asset's current state.

Clearside - CLSD Company Value to EBITDA (period 11/23/2025 - 12/13/2025)

Summary analytical data breakdowns for clearsidebio.com (CLSD)

- current price and projected stock value:
Stock Price Clearside|CLSD - Average Forecast Price
- company stock capitalization data:
Market Valuation Clearside Corp|CLSD - Total Enterprise Value
- business book valuation details:
Book Value per Share Clearside Biomedical|CLSD - Total Stockholders' Equity|Market Value to Book Value Ratio clearsidebio.com|CLSD - Company Total Asset Base
- debt and liquidity data:
Total Debt to Capital Clearside Biomedical|CLSD - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Clearside Biomedical, Inc.|CLSD - Company Debts|Debts to Book Capitalization Clearside Corp|CLSD - Long-Term Debt|Company Short-Term Debts Clearside Biomedical|Quick Liquidity clearsidebio.com
- financial results and valuation multiples details:
CLSD - Final Profit|Expected Profit Clearside Biomedical|CLSD - Business Payback Period|Forward P/E Multiple Clearside Biomedical|CLSD - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Clearside Corp|CLSD - Operating profit before amortization|Net earnings per share (EPS TTM) Clearside Biomedical|CLSD - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months clearsidebio.com|CLSD - Earnings per share increase in current year|Earnings growth forecast for next year Clearside Biomedical
Summary company analytics:Clearside CLSD
Product sample of Clearside Biomedical, Inc.

The EV/EBITDA multiple compares the total enterprise value, including net debt, with operating profit before interest, taxes, depreciation, and amortization, allowing for an assessment of the real value of assets regardless of the financing structure. Analyzing the business valuation level via EV/EBITDA helps determine if an asset is overvalued, which is critical for Clearside Biomedical (CLSD), whose microinjection patents create a unique market barrier and drive long-term capitalization.

Competitor analysis

EV/EBITDA Multiple ALC (Alcon Vision)|Bausch Health (BLCO) - Company Value to EBITDA|GKOS: Enterprise Value to EBITDA Ratio|Company Value to EBITDA apellis.com|BLTE: EV/EBITDA Multiple|Company Value to EBITDA Ocular Therapeutix Inc (OCUL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harrow Health|Viridian Corp (VRDN) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple LENZ|Enterprise Value to EBITDA Ratio Oculis Holding AG OCS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization EyePoint Pharmaceuticals, Inc. EYPT|Kodiak Sciences Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Aldeyra - EV/EBITDA Multiple|Company Value to EBITDA KALA BIO, Inc.|IRD: EV/EBITDA Multiple|OKYO Pharma (OKYO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adverum Biotechnologies Inc.|OTLK: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NovaBay Pharmaceuticals (NBY)|Total Company Value to Operating Income Before Depreciation Ratio kiorapharma.com|EV/EBITDA Multiple ALIM (Alimera Sciences, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Eyenovia Inc. (EYEN)|Guardion Health Sciences - EV/EBITDA Multiple|OCUP (Ocuphire Pharma Inc) - Enterprise Value to Operating Income Before Depreciation|OPT: EV/EBITDA Multiple